MedPath

Characterisation of chylomicron size distribution in subjects with metabolic syndrome: The effect of dietary fatty acid composition.

Not Applicable
Conditions
Metabolic syndrome
Metabolic and Endocrine - Metabolic disorders
Registration Number
ACTRN12614000352606
Lead Sponsor
Curtin University, School of Public Health
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

must have abdominal obesity (waist circumference for males equal to or greater than 94 cm and females equal to or greater than 80 cm) and raised triglycerides (fasting TAG equal to or greater than 1.7 mmol/L) and one of the following factors: reduced serum HDL cholesterol less than 1.03 mmol/L in males and less than 1.29/L in females; impaired fasting glycemia (fasting plasma glucose equal to or greater than 5.6 mmol/L; or raised BP systolic equal to or greater than 130 mmHg or diastolic equal to or greater than 85 mmHg. The control group will be lean normolipidemic gender- and age-matched controls.

Exclusion Criteria

pregnant, in lactation, smoking, excess alcohol intake (greater than 2 Australian standard drink/day), use of lipid lowering medication, prior cardiovascular, hepatic or renal disease, greater than +/- 5 kg changes in the previous 6 months, have intention for losing weight in the next 6 months, on a dietary advice, taking dietary supplements (e.g. fish oil), history or current use of glucocorticosteroids, insulin and/or thiazolidinediones, or gastric disturbances.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Apolipoprotein B-48 response in plasma, chylomicron fraction, VLDL fraction and denser fraction. Area and incremental area under curve (AUC and IAUC) will be calculated using the trapezoidal rule (Matthews, 1988). Differences in postprandial responses between different test meals and between groups will be analysed by using repeated measures ANOVA within-between group factors with interaction. The detection of significant pairwise interactions will be done using the Bonferroni post hoc test. A p value less than 0.05 will be considered significant.[Baseline, at 2, 4, 6 and 8 hours after the test meal.]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath